These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 6783943

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Annual report: evaluation of new compounds for opioid activity (1980).
    Woods JH, Medzihradsky F, Smith CB, Young AM, Swain HH.
    NIDA Res Monogr; 1981 Feb; 34():327-66. PubMed ID: 6783945
    [No Abstract] [Full Text] [Related]

  • 7. Biological evaluation of compounds for their physical dependence potential and abuse liability. XIII. Drug Testing Program of the Committee on Problems of Drug Dependence, Inc.
    Jacobson AE.
    NIDA Res Monogr; 1989 Feb; 95():556-77. PubMed ID: 2641053
    [No Abstract] [Full Text] [Related]

  • 8. Antagonists in the 5-phenyl-benzomorphan series.
    Clarke FH, Hill RT, Saelens JK, Yokoyama N.
    Adv Biochem Psychopharmacol; 1973 Feb; 8(0):81-9. PubMed ID: 4211809
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical pharmacology of narcotics. II].
    Fernandes M.
    Hippokrates; 1972 Dec; 43(4):464-83. PubMed ID: 4657127
    [No Abstract] [Full Text] [Related]

  • 10. Biological evaluation of compounds for their physical dependence potential and abuse liability. IX. Drug Testing Program of the Committee on Problems of Drug Dependence, Inc. (1985).
    Jacobson AE.
    NIDA Res Monogr; 1986 Dec; 67():385-98. PubMed ID: 3092095
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biological evaluation of compounds for their physical dependence potential and abuse liability. XII. Drug testing program of the Committee on Problems of Drug Dependence, Inc. (1988).
    Jacobson A.
    NIDA Res Monogr; 1988 Dec; 90():392-420. PubMed ID: 2908336
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biological evaluation of compounds for their physical dependence potential and abuse liability. XVI. Drug Evaluation Committee of the College of Problems of Drug Dependence, Inc. (1992).
    Jacobson AE.
    NIDA Res Monogr; 1993 Dec; 132():437-58. PubMed ID: 8101975
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biological evaluation of compounds for their physical dependence potential and abuse liability, XIV. Animal Testing Committee of the Committee on Problems of Drug Dependence, Inc. (1991).
    Jacobson AE.
    NIDA Res Monogr; 1992 Dec; 119():490-512. PubMed ID: 1435983
    [No Abstract] [Full Text] [Related]

  • 17. Contribution of 'receptor' affinity to analgesic potency.
    Terenius L.
    J Pharm Pharmacol; 1974 Feb; 26(2):146-8. PubMed ID: 4132633
    [No Abstract] [Full Text] [Related]

  • 18. Biological evaluation of compounds for their physical dependence potential and abuse liability. XIV. Animal Testing Committee of the Committee on Problems of Drug Dependence, Inc. (1990).
    Jacobson AE.
    NIDA Res Monogr; 1990 Feb; 105():622-39. PubMed ID: 1876149
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Analgesic and dependence studies with oripavine partial agonists.
    Cowan A, Lewis JW, Macfarlane IR, Whittle BA.
    Br J Pharmacol; 1971 Oct; 43(2):461P-462P. PubMed ID: 5168272
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.